Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-05-15T10:36:11.655Z Has data issue: false hasContentIssue false
  • English
  • Français

Beneficial effect of the addition of the 5-HT 2A/2C and α2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients

Published online by Cambridge University Press:  16 April 2020

A. Grinshpoon ,
A. Valevski ,
M. Moskowitz  and
A. Weizman
A. Grinshpoon
Affiliation:
Mental Health Service, Israel Ministry of Health and Israel Defense Force, Petah Tiqva, Israel
A. Valevski
Affiliation:
Geha Psychiatric Hospital and Felsenstein Medical Research Center, Beilinson Campus, Petah Tiqva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
M. Moskowitz
Affiliation:
Neve Yaakov Psychiatric Hospital, Petah Tiqva, Israel
A. Weizman*
Affiliation:
Geha Psychiatric Hospital and Felsenstein Medical Research Center, Beilinson Campus, Petah Tiqva, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
*
*Correspondence and reprints: A. Weizman, MD, Geha Psychiatric Hospital, Beilinson Campus, Petah Tiqva 49100, Israel
Get access

Summary

Atypical neuroleptics that block serotonin 2A (5-HT 2A) and dopamine 2 (D2) receptors have been shown to possess efficacious antipsychotic activity. We assessed the efficacy of the addition of the 5-HT 2A/2C and α2 antagonist mianserin to ongoing haloperidol treatment in chronically hospitalized (> 10 years) drug-resistant schizophrenic patients (N = 12). The patients were assessed at baseline and every three months for one year with the Brief Psychiatric Rating Scale and the Clinical Global Impression. Results showed a significant (but < 10%) improvement in the core symptoms of schizophrenia; however, only the reduction (by 43%) in anxiety was clinically relevant (P < 0.0001). The beneficial effect of mianserin may be related to the combined blockade of 5-HT 2A and histamine (H1) receptors.

Keywords

anxietydopaminehaloperidolmianserinschizophreniaserotonin
Type
Short Communication
Information
European Psychiatry , Volume 15 , Issue 6 , September 2000 , pp. 388 - 390
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Charney, D.S, Woods, S.W, Goodman, W.K, Heninger, G.RNeurobiological mechanisms of panic anxiety: biochemical and behavioural correlates of yohimbine-induced panic attacks Am J Psychiatry 144 1987 1030–1036Google Scholar
Coffey, IOptions for the treatment of negative symptoms of schizophrenia CNS Drugs 1 1994 107–11810.2165/00023210-199401020-00003CrossRefGoogle Scholar
Diaz-Martinez, A, Gutierrez-Aguilar, J, Alvarez-Rueda, M, Ortega-Soto, H.AMianserin as an adjuvant therapy in the treatment of schizophrenia: an open study New Trends Exp Clin Psychiat 14 1998 27–32Google Scholar
Gelders, Y.G, Bussche, G.V, Reyntjens, A, Janssen, J.A.PSerotonin S2 blockers in the treatment of chronic schizophrenia Clin Neuropharmacol 9 1986 325–327Google Scholar
Gelders, Y.GThymosthenic agents, a novel approach in the treatment of schizophrenia Br J Psychiatry 1989 33–3610.1192/S0007125000295950CrossRefGoogle ScholarPubMed
Guy, WClinical global impressions. Early clinical drug evaluation unit (ECDEU) Nat Inst Health 55 1976 218–222Google Scholar
Holmberg, G, Gershon, SAutonomic and psychic effects of yohimbine hydrochloride Psychopharmacologia 2 1961 93–10610.1007/BF00592678CrossRefGoogle ScholarPubMed
Ikeguchi, K, Kuroda, AMianserin treatment of patients with psychosis induced by antiparkinsonian drugs Eur Arch Psychiatry Clin Neurosci 244 1995 320–32410.1007/BF02190411CrossRefGoogle ScholarPubMed
Kapur, S, Remington, GSerotonin-dopamine interaction and its relevance to schizophrenia Am J Psychiatry 153 1996 466–476Google Scholar
Louwerens, J.W, Coppens, H.C, Korf, J, Slooff, C.J, Paans, A.M.G, Vaalburg, WOn the pathogenetic role of dopaminergic and serotonergic neurotransmission in longterm hospitalized psychotic patients Schizophr Res 3 1990 525210.1016/0920-9964(90)90134-SCrossRefGoogle Scholar
Meltzer, H.YTreatment of the neuroleptic nonresponsive schizophrenic patient Schizophr Bull 18 1992 515–53410.1093/schbul/18.3.515CrossRefGoogle ScholarPubMed
Mizuki, Y, Kajimura, N, Imai, T, Seutsugi, M, Kai, S, Kaneyuki, H et al. Effects of mianserin on negative symptoms in schizophrenia Int Clin Psychopharmacol 5 1990 83–9510.1097/00004850-199004000-00002CrossRefGoogle Scholar
Mizuki, Y, Kajimura, N, Kai, S, Suetsugi, M, Ushiuima, I, Yamada, MEffects of mianserin in chronic schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 16 1992 917–928Google ScholarPubMed
Overall, J, Gorham, DBrief Psychiatry Rating Scale Psychol Rep 10 1962 799–81210.2466/pr0.1962.10.3.799CrossRefGoogle Scholar
Pinder, R.M, Fink, MMianserin Mod Probl Pharmacopsychiatry 18 1982 70–101CrossRefGoogle ScholarPubMed
Reyntjens, A, Gelders, Y.G, Hoppenbrouwers, M.L.J.A, van den Bussche, GThymostenic effects of ritanserin (R55667), a centrally acting serotonin-S2 receptor blocker Drug Rev Res 8 1986 205–21110.1002/ddr.430080124CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.